Treatment of lentigo maligna with tazarotene 0.1% gel

Journal of the American Academy of Dermatology

Volumn 50, Issue 1, 2004, Pages 101-103

  Chimenti, Sergio ^a   Carrozzo, Anna Maria ^a   Citarella, Luigi ^a   De Felice, Catia ^a   Peris, Ketty ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TAZAROTENE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; CRYOSURGERY; CURETTAGE; DESICCATION; ERYTHEMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MALE; MALIGNANT LENTIGO; PRIORITY JOURNAL; PRURITUS; SKIN BIOPSY; TREATMENT OUTCOME;

EID: 0346373728     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.07.005     Document Type: Article

References (16)

1. Mahendran R, Newton-Bishop JA. Survey of UK current practice in the treatment of lentigo maligna. Br J Dermatol 2001;144: 71-6.
2. Arndt KA. Argon laser treatment of lentigo maligna. J Am Acad Dermatol 1984;10:953-7.
3. Kopera D. Treatment of lentigo maligna with the carbon dioxide laser. Arch Dermatol 1995;131:735-6.
4. Orten SS, Waner M, Dinehart SM, Bardales RH, Flock ST. Q-switched neodymium: yttrium-aluminium-garnet laser treatment of lentigo maligna. Otolaryngol Head Neck Surg 1999;120: 296-302.
5. Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002;146:1042-6.
6. Cornejo P, Vanaclocha F, Polimon I, Del Rio R. Intralesional interferon treatment of lentigo maligna. Arch Dermatol 2000;136: 428-30.
7. Nazzaro-Porro M, Passi S, Zina G, Breathnach AS. Ten years' experience of treating lentigo maligna with topical azelaic acid. Acta Derm Venereol 1989;143:49-57.
8. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000;143:843-5.
9. Duvic M, Helekar B, Schulz C, Cho M, DiSepio D, Hager C, et al. Expression of retinoid-inducible tumor suppressor, tazarotene-inducible Gene-3, is decreased in psoriasis and skin cancer. Clin Cancer Res 2000;6:3249-59.
10. Hofmann B, Stege H, Ruzicka T, Lehmann P. Effect of topical tazarotene in the treatment of congenital ichthyoses. Br J Dermatol 1999;141:642-6.
11. Burkhart CG, Burkhart CN. Tazarotene gel for Darier's disease. J Am Acad Dermatol 1998;38:1001-2.
12. Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal cell carcinoma. N Engl J Med 1999;341:1767-8.
13. McLean DI, Peter KK. Apparent progression of lentigo maligna to invasive melanoma during treatment with topical azelaic acid. Br J Dermatol 1986;114:685-9.
14. Litwin MS, Krementz ET, Mansell PW, Reed RJ. Topical chemotherapy of lentigo maligna with 5-fluorouracil. Cancer 1975;35: 721-33.
15. Rivers JK, McCarthy WH. No effect of topical tretinoin on lentigo maligna. Arch Dermatol 1991;127:129.
16. Steinmann A, Funk JO, Schuler G, von der Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000;43:555-6.